Genzyme Sues Lupin Over Generic Renagel

Law360, New York (March 6, 2009, 12:00 AM EST) -- Biotechnology company Genzyme Corp. has sued Lupin Pharmaceuticals Inc. to prevent it from marketing a generic version of Renagel, a drug used to treat serum phosphorus in chronic kidney disease patients on dialysis.

In a complaint filed Friday with the U.S. District Court for the District of Delaware, Cambridge, Mass.-based Genzyme accused Lupin of patent infringement.

According to the complaint, Lupin – a subsidiary of the Indian drug manufacturer Lupin Ltd. – infringed four of Genzyme's patents by filing an abbreviated new drug application for sevelamer...
To view the full article, register now.